Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Gsk

Evaluate

Thumbnail
March 23, 2023

Dupixent pushes towards a big new use

March 02, 2023

GSK gets the vaccine edge on Pfizer

US experts favour GSK’s RSV vaccine over Pfizer’s, but both could be on the market soon.

Article image
Vantage logo
March 01, 2023

US FDA approval tracker: February 2023

Article image
Vantage logo
February 28, 2023

Go or no go? Vaccines and neurology up for discussion

FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin.

Article image
Vantage logo
February 27, 2023

CROI 2023 – GSK and Gilead’s long-acting HIV battle intensifies

GSK shows that Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to go even longer.

Article image
Vantage logo
February 17, 2023

Asco-GU – Talzenna remains a wait-and-see story in prostate cancer

Talapro-2 data backing Talzenna in all-comers are slated by Asco-GU’s discussant, as Lynparza shows precisely what might go wrong.

Article image
Vantage logo
February 17, 2023

Moderna’s post-Covid prospects dim

Article image
Vantage logo
February 16, 2023

Sanofi and Regeneron face a high-risk test for Dupixent

A pivotal readout approaches in COPD, where other biologicals have fallen short.

Article image
Vantage logo
February 15, 2023

Asco-GU – Bicycle tries to put distance between itself and Seagen

However, results with BT8009, one of several datasets being presented this week at the Asco-GU conference, fail to convince many investors.

Article image
Vantage logo
February 10, 2023

Jemperli moves towards neoadjuvant rectal cancer at last

Article image
Vantage logo
February 09, 2023

Biopharma and Medtech Review 2022

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up